CTL 020 and Tumor 020 are proprietary, patient derived colon cancer cell lines developed at the Wistar Institution. These cell lines are well characterized and have been tested extensively across multiple assay formats. We have the exclusive, commercial license to this HLA-matched cell line pairing. This cell line pairing has been tested and proven responsive to Keytruda (anti-PD1). Data available upon request.

Study Design

This assay is designed to measure the effect of test drug candidates on CTL 020 and Tumor 020 in comparison with Keytruda (anti-PD1). This assay will be run in 24 well plate for a 4-day co-culture period. The assay will measure the effect of test drug candidates on the following:

  • CTL 020 migration
  • Cytokine responses (Multiplex of 13 cytokines)
  • Quantification of apoptosis

Study Arms

  • CTL 020 + Tumor 020 (No Compound)
  • Tumor 020
  • CTL 020 + Tumor 020 +DMSO
  • CTL 020 + Tumor 020 + Keytruda (anti-PD1)

The assay will be run in duplicates (2)


  • Raw data for flow cytometry (.fcs files)  – client must have Flowjo or other software to read files
  • Raw data of multiplex cytokines
  • Image sections (one per well)
  • Powerpoint presentation of the data

Reference Study using Keytruda (anti-PD1)

Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture

Cancer Immunol Immunother (2007) 56:359–370

Notes for Clients

  • Minimum of 2 test compounds must be submitted
  • Each dose is run in duplicates (e.g. if one test compound has 3 doses = 6 wells will be used)
  • Keytruda (anti-PD1) control at 10ug/ml
  • Client must provide dose and handling instructions at time of delivery of drug candidates
  • If no dilution or concentration buffer provided, we will assume the use of DMSO as thed dilution of buffer
  • If Client is a member of Scientist.com, Purchase Order (PO) must be submitted via Scientist.com
  • Deliverables include – raw data files for cytokines and .fcs for flow cytometry
  • Price includes one (1) round of revision within 5 days from receipt of data. If more time and additional rounds of revision are needed, please contact us – info@immune3d.com
  • A 30% upfront fee of the PO is required to secure a position
  • Cancellations are not accepted once the drug candidate is received in house